EcoDrugPlus

Cholinergic Receptor Nicotinic Beta 2 Subunit

Ensembl ID : ENSMMNG00015013953
Gene Symbol: CHRNB2
3 Cross references
197 Possible Orthologues:

Cholinergic Receptor Nicotinic Beta 4 Subunit

Ensembl ID : ENSMMNG00015011019
Gene Symbol: CHRNB4
3 Cross references
198 Possible Orthologues:

Chymase 1

Ensembl ID : ENSMMNG00015016383
Gene Symbol: CMA1
1 Cross references
293 Possible Orthologues:

Coagulation Factor Ii Thrombin Receptor

Ensembl ID : ENSMMNG00015007933
Gene Symbol: F2R
3 Cross references
327 Possible Orthologues:

Coagulation Factor Ii, Thrombin

Ensembl ID : ENSMMNG00015019642
Gene Symbol: F2
3 Cross references
85 Possible Orthologues:

Coagulation Factor Iii, Tissue Factor

Ensembl ID : ENSMMNG00015008161
Gene Symbol: F3
3 Cross references
243 Possible Orthologues:

Coagulation Factor Vii

Ensembl ID : ENSMMNG00015016773
Gene Symbol: F7
3 Cross references
274 Possible Orthologues:

Coagulation Factor X

Ensembl ID : ENSMMNG00015016667
Gene Symbol: F10
3 Cross references
237 Possible Orthologues:

Coagulation Factor Xi

Ensembl ID : ENSMMNG00015012306
Gene Symbol: F11
1 Cross references
216 Possible Orthologues:

Coiled-Coil Domain Containing 6

Ensembl ID : ENSMMNG00015014903
Gene Symbol: CCDC6
3 Cross references
219 Possible Orthologues:

Colony Stimulating Factor 1 Receptor

Ensembl ID : ENSMMNG00015002039
Gene Symbol: CSF1R
3 Cross references
206 Possible Orthologues:

Complement C1s

Ensembl ID : ENSMMNG00015016694
Gene Symbol: C1S
3 Cross references
199 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).